|
1）Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2009; 54: S55-66
|
|
|
|
2）Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The task force for the diagnosis and treatment of pulmonary hyperten-sion of the European Society of Cardiology (ESC) and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009; 30: 2493-537
|
|
|
|
|
|
3）Mukerjee D, St George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hyperten-sion in systemic sclerosis. Rheumatology (Oxford). 2004; 43: 461-6
|
|
|
|
|
|
4）Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospec-tive multicenter study. Arthritis Rheum. 2005; 52: 3792-800
|
|
|
|
|
|
5）Hinchcliff M, Fischer A, Schiopu E, et al. Pulmonary hypertension assessment and recog-nition of outcomes in scleroderma (PHAROS): Baseline characteristics and description of study population. J Rheumatol. 2011; 38: 2172-9
|
|
|
|
|
|
6）Schreiber BE, Valerio CJ, Keir GJ, et al. Improving the detection of pulmonary hyperten-sion in systemic sclerosis using pulmonary func-tion tests. Arthritis Rheum. 2011; 63: 3531-9
|
|
|
|
|
|
7）Cavagna L, Caporali R, Klersy C, et al. Com-parison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol. 2010; 37: 2064-70
|
|
|
|
|
|
8）Williams MH, Handler CE, Akram R, et al. Role of n-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J. 2006; 27: 1485-94
|
|
|
|
|
|
9）Steen V, Chou M, Shanmugam V, et al. Exercise-induced pulmonary arterial hypertension in patients with systemic sclerosis. Chest. 2008; 134: 146-51
|
|
|
|
|
|
10）Tamura Y, Ono T, Kuwana M, et al. Human pentraxin 3 (PTX3) as a novel biomarker for the diagnosis of pulmonary arterial hypertension. PLoS One. 2012; 7: e45834
|
|
|
|
|
|
11）Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173: 1023-30
|
|
|
|
|
|
12）Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009; 179: 151-7
|
|
|
|
|
|
13）Shirai Y, Yasuoka H, Okano Y, et al. Clinical characteristics and survival of Japanese patients with connective tissue disease and pulmonary arterial hypertension: a single-centre cohort. Rheumatology (Oxford). 2012; 51: 1846-54
|
|
|
|
|
|
14）Jais X, Launay D, Yaici A, et al. Immuno-suppressive therapy in lupus- and mixed connec-tive tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum. 2008; 58: 521-31
|
|
|
|
|
|
15）Miyamichi-Yamamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J. 2011; 75: 2668-74
|
|
|
|
|
16）Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmo-nary arterial hypertension from REVEAL: identi-fying systemic sclerosis as a unique phenotype. Chest. 2010; 138: 1383-94
|
|
|
|
|
|
17）Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med. 2009; 179: 151-7
|
|
|
|
|
|
18）McLaughlin VV, McGoon MD. Pulmonary arterial hypertension. Circulation. 2006; 114: 1417-31
|
|
|
|
|